Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Consensus Target Price of $21.17 According to Analysts

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) have earned a consensus recommendation of “Moderate Buy” from the sixteen research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $21.50.

A number of equities analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, August 10th. JPMorgan Chase & Co. upped their price objective on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Wall Street Zen upgraded shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Stifel Nicolaus lifted their target price on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, October 15th.

Insider Activity

In other news, CFO Dominic Piscitelli sold 14,000 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total value of $189,420.00. Following the transaction, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $944,772.84. The trade was a 16.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock valued at $1,432,952 over the last 90 days. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Oric Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Oric Pharmaceuticals in the 2nd quarter valued at approximately $73,904,000. Siren L.L.C. increased its position in Oric Pharmaceuticals by 197.6% in the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after buying an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP increased its position in Oric Pharmaceuticals by 19.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock worth $18,637,000 after buying an additional 244,060 shares during the period. Algert Global LLC lifted its holdings in shares of Oric Pharmaceuticals by 791.3% during the second quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock worth $13,162,000 after buying an additional 1,078,943 shares during the last quarter. Finally, Braidwell LP lifted its holdings in shares of Oric Pharmaceuticals by 7.7% during the second quarter. Braidwell LP now owns 1,214,540 shares of the company’s stock worth $13,153,000 after buying an additional 86,500 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $8.95 on Friday. The business’s 50-day simple moving average is $12.85 and its 200-day simple moving average is $11.14. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.68. The firm has a market cap of $927.67 million, a price-to-earnings ratio of -6.63 and a beta of 0.99.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, equities research analysts forecast that Oric Pharmaceuticals will post -1.53 earnings per share for the current year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.

Oric’s pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.